Perspective Therapeutics (NASDAQ:CATX) Rating Increased to Strong-Buy at Piper Sandler

Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other research analysts also recently issued reports on the company. B. Riley Financial lowered their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. HC Wainwright raised their price target on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, January 30th. BTIG Research reissued a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, January 13th. UBS Group lowered their price objective on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $11.86.

Perspective Therapeutics Stock Up 12.3%

Shares of CATX opened at $5.65 on Thursday. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16. The company has a market capitalization of $420.01 million, a P/E ratio of -6.28 and a beta of 1.75. The firm’s 50 day moving average price is $3.36.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CATX. Aigen Investment Management LP bought a new position in Perspective Therapeutics in the 4th quarter worth $28,000. nVerses Capital LLC purchased a new position in shares of Perspective Therapeutics during the 4th quarter valued at about $31,000. Engineers Gate Manager LP bought a new position in shares of Perspective Therapeutics during the 4th quarter valued at approximately $35,000. AXQ Capital LP increased its holdings in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after acquiring an additional 2,481 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $42,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.